These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 32192306)

  • 21. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer.
    He F; Yu L; Ding Y; Li ZH; Wang J; Zheng J; Chen HY; Liu S; Pang XL; Ajani JA; Wan XB
    Cancer Sci; 2020 Nov; 111(11):4205-4217. PubMed ID: 32860448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer.
    Zhang S; Zhang R; Li RZ; Wang QX; Chang H; Ding PR; Li LR; Wu XJ; Chen G; Zeng ZF; Xiao WW; Gao YH
    Cancer Sci; 2021 Sep; 112(9):3607-3615. PubMed ID: 34146368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
    Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
    [No Abstract]   [Full Text] [Related]  

  • 26. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study.
    Lupattelli M; Palazzari E; Polesel J; Chiloiro G; Angelicone I; Panni V; Caravatta L; Di Biase S; Macchia G; Niespolo RM; Franco P; Epifani V; Meldolesi E; de Giacomo F; Lucarelli M; Montesi G; Mantello G; Innocente R; Osti MF; Gambacorta MA; Aristei C; De Paoli A
    Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy].
    Li YH; Qiu XY; Lin GL; Zhou JL; Xiao Y; Qiu HZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):344-351. PubMed ID: 33878824
    [No Abstract]   [Full Text] [Related]  

  • 29. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
    BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.
    Wang QX; Zhang R; Xiao WW; Zhang S; Wei MB; Li YH; Chang H; Xie WH; Li LR; Ding PR; Chen G; Zeng ZF; Wang WH; Wan XB; Gao YH
    Radiat Oncol; 2021 Jan; 16(1):16. PubMed ID: 33468176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].
    Jin Y; Zhai ZW; Sun LT; Xia PD; Hu H; Jiang CQ; Zhao BC; Qu H; Qian Q; Dai Y; Yao HW; Wang ZJ; Han JG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):403-411. PubMed ID: 38644246
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI-detected extramural venous invasion.
    Chen M; Ma Y; Song YW; Huang J; Gao YH; Zheng J; He F
    Cancer Med; 2023 Nov; 12(21):20523-20537. PubMed ID: 37864414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.
    Chen W; Wang W; Huang S; Zhou L; Wang G; Chen W
    Cancer Invest; 2024 Aug; 42(7):661-670. PubMed ID: 39037150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
    Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
    Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
    Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
    J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    Garcia-Aguilar J; Patil S; Gollub MJ; Kim JK; Yuval JB; Thompson HM; Verheij FS; Omer DM; Lee M; Dunne RF; Marcet J; Cataldo P; Polite B; Herzig DO; Liska D; Oommen S; Friel CM; Ternent C; Coveler AL; Hunt S; Gregory A; Varma MG; Bello BL; Carmichael JC; Krauss J; Gleisner A; Paty PB; Weiser MR; Nash GM; Pappou E; Guillem JG; Temple L; Wei IH; Widmar M; Lin S; Segal NH; Cercek A; Yaeger R; Smith JJ; Goodman KA; Wu AJ; Saltz LB
    J Clin Oncol; 2022 Aug; 40(23):2546-2556. PubMed ID: 35483010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.